Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 13,700 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler acquired 13,700 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was acquired at an average cost of $24.01 per share, for a total transaction of $328,937.00. Following the transaction, the director owned 540,810 shares of the company’s stock, valued at approximately $12,984,848.10. The trade was a 2.60% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Biodesix Stock Performance

Shares of BDSX stock opened at $24.22 on Thursday. Biodesix, Inc. has a 52 week low of $5.26 and a 52 week high of $25.52. The company has a debt-to-equity ratio of 5.12, a quick ratio of 2.85 and a current ratio of 2.85. The firm’s 50-day simple moving average is $20.19 and its two-hundred day simple moving average is $16.05. The firm has a market cap of $255.52 million, a price-to-earnings ratio of -7.64 and a beta of 0.56.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.19. Biodesix had a negative return on equity of 788.19% and a negative net margin of 26.97%.The company had revenue of $26.86 million during the quarter, compared to the consensus estimate of $26.03 million. As a group, equities analysts forecast that Biodesix, Inc. will post -2.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

BDSX has been the subject of a number of analyst reports. Canaccord Genuity Group raised their price target on Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective (up from $26.00) on shares of Biodesix in a research note on Thursday, August 6th. Roth Capital initiated coverage on Biodesix in a report on Wednesday, June 24th. They set a “buy” rating and a $32.00 price objective on the stock. Finally, Weiss Ratings upgraded Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Biodesix currently has an average rating of “Moderate Buy” and a consensus target price of $31.33.

Institutional Trading of Biodesix

Hedge funds have recently made changes to their positions in the stock. AIGH Capital Management LLC purchased a new position in shares of Biodesix in the 1st quarter worth about $10,996,000. XTX Topco Ltd boosted its stake in Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares in the last quarter. Monashee Investment Management LLC grew its position in Biodesix by 12.3% during the fourth quarter. Monashee Investment Management LLC now owns 112,344 shares of the company’s stock valued at $764,000 after acquiring an additional 12,348 shares during the last quarter. Walleye Capital LLC bought a new position in Biodesix during the second quarter valued at approximately $1,679,000. Finally, Stempoint Capital LP purchased a new position in shares of Biodesix during the first quarter worth approximately $1,015,000. 20.96% of the stock is owned by institutional investors.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.